Expiration date: 07/2026

Action: 

hypoglycemic drug. Stimulates the release of insulin from functioning beta cells of the pancreas

Composition:

Repaglinide 0.5, 1 or 2 mg

Subsidiary in the Islands: poloxamer, meglumine , lactose monohydrate, cellulose microcrystalline , polacrilin potassium , silicon dioxide colloidal, magnesium stearate

Indications:

diabetes mellitus type 2 (with the ineffectiveness of diet, weight loss and physical activity) in monotherapy or in combination with Metformin or thiazolidinedione in cases where fails to achieve satisfactory glycemic control with monotherapy Repaglinide or Metformin or thiazolidinedione.